Page 28 - David Ricks News Today

CHICAGO (Reuters) -An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-...

The drug, donanemab, slowed progression of Alzheimer’s by 35% to 36% compared to a placebo in 1,182 people

Lilly plans to proceed with global regulatory submissions for donanemab as soon as possible and will make a submission to the FDA this quarter.

CHICAGO, May 3 (Reuters) - An experimental Alzheimer's drug developed by Eli Lilly and Co (LLY.N) slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35pc in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease.

Patients who have taken Eli Lilli's weight-loss drug, Tirzepatide, lost an average of up to 34 pounds, or 16% of her body weight, the company said in clinical

Eli Lilly's earnings call on Thursday included a frank discussion of the chronic nature of weight loss treatment.

Following positive Phase 3 data, the pharma giant said it’s using a priority review voucher to ensure expedited review of Mounjaro for weight loss.

Eli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.

BioPharma